|
Values
|
P
a
|
---|
Subject number
|
45
| |
Age
|
51.53 ± 10.30
|
<0.001
|
Gender
| |
0.034
|
Male
|
33 (73.33%)
| |
Female
|
12 (26.67%)
| |
Liver Histology
|
ISHAK Fibrosis Stages
| |
<0.001
|
1
|
7 (15.56%)
| |
2
|
5 (11.11%)
| |
3
|
13 (28.89%)
| |
4
|
6 (13.33%)
| |
5
|
10 (22.22%)
| |
6
|
14 (31.11%)
| |
Piecemeal necrosis
| |
0.07
|
0
|
10 (22.22%)
| |
1
|
23 (51.11%)
| |
2
|
6 (13.33%)
| |
3
|
6 (13.33%)
| |
Confluent necrosis
| |
0.165
|
0
|
40 (88.89%)
| |
4
|
5 (11.11%)
| |
Focal (spotty) lytic necrosis, apoptosis and focal inflammation
| |
0.329
|
1
|
14 (31.11%)
| |
2
|
27 (60.00%)
| |
3
|
4 (8.89%)
| |
Portal inflammation
| |
0.114
|
0
|
2 (4.44%)
| |
1
|
13 (28.89%)
| |
2
|
6 (13.33%)
| |
3
|
23 (51.11%)
| |
4
|
1 (2.22%)
| |
Viral serology
|
HBV DNA (log10 IU/ml)
|
5.31 ± 1.68
|
<0.001
|
HBsAg (log10 IU/ml)
|
2.79 ± 0.90
|
<0.001
|
Hematology
|
ALT (IU/L)
|
141.00 ± 124.94
|
0.087
|
AST (IU/L)
|
91.29 ± 83.45
|
0.277
|
Bilirubin (mg/dL)
|
0.90 ± 0.28
|
0.119
|
Albumin (g/dL)
|
4.45 ± 0.28
|
0.196
|
Gamma-glutamyltransferase (IU/L)
|
66.20 ± 65.26
|
0.626
|
Platelet (1000/mm3)
|
179.36 ± 53.17
|
0.22
|
Hemoglobin (g/dL)
|
14.69 ± 1.29
|
0.032
|
-
a Compared with the model-construction cohort